查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亨丁顿舞蹈症的全球市场:市场规模 - 各治疗法，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1189196

亨丁顿舞蹈症的全球市场:市场规模 - 各治疗法，各地区展望，竞争策略，各市场区隔预测(～2032年)

Huntington's Disease Market Size-By Treatment - Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 225 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球亨丁顿舞蹈症的市场规模，预计至2032年达到26亿5,000万美元，以19.83％的年复合成长率成长。

新产品创造的大数量的研究开发费，研究联盟，欧美各国的亨丁顿舞蹈症的高盛行率等，使全球市场扩大。

本报告提供全球亨丁顿舞蹈症市场相关调查，市场动态，竞争情形，各治疗方法、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球亨丁顿舞蹈症市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 竞争情形

  • 全球亨丁顿舞蹈症的製造地分布，销售区域，产品类型
  • 全球亨丁顿舞蹈症市场的合併、收购，伙伴关係，产品的销售，合作

第7章 全球亨丁顿舞蹈症市场:各治疗法(2019年～2032年(100万美元))

  • 对症疗法
  • 疾病修正治疗

第8章 全球亨丁顿舞蹈症市场:各地区(2019年～2032年(100万美元))

  • 全球亨丁顿舞蹈症的市场规模、市场占有率:各地区(2019年～2025年)
  • 全球亨丁顿舞蹈症的市场规模、市场占有率:各地区(2026年～2032年)
  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的亚太地区
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的欧洲
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲
  • 北美
    • 加拿大
    • 墨西哥
    • 美国
  • 南美
    • 阿根廷
    • 巴西
    • 其他的南美

第9章 企业简介

  • Annexon Biosciences
    • 企业概要
    • 财务预测
    • 产品概要
    • 最近的开发
  • Bausch Health Companies Inc.
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly And Company
  • H. Lundbeck A/S
  • Hetero
  • Hikma Pharmaceuticals PLC
  • Lupin
  • Medesis pharma SA
  • Mitochon Pharmaceuticals
  • Neurocrine bioscience Inc.
  • Novartis
  • PTC Therapeutics, Inc.
  • SOM Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UniQure
  • Vaccinex, Inc.

第10章 简称一览

第11章 参照链接

第12章 结论

第13章 调查范围

简介目录
Product Code: HLCA2237

Global Huntington's Disease Market Overview:

According to SPER Market Research, the Global Huntington's Disease Market is estimated to reach USD 2.65 billion by 2032 with a CAGR of 19.83%.

The global market for Huntington's disease is expanding as a result of significant R&D expenditures for the creation of novel products, research partnerships, and the high prevalence of HD in western nations. An uncommon hereditary neurological disorder that affects multiple generations, is Huntington's disease. People in adult age are affected, which limits their ability to work, take care of their families, and finally finish everyday duties. The numbers vary between regions, which can be attributed to differences in case ascertainment and diagnostic standards. Also, the incidence varies between regions, which can be attributed to differences in case ascertainment and diagnostic standards. As a result, larger repeats may be more common than anticipated in the general population. While Europe, North America, and Australia have greater prevalence's, the Asian population has continuously had a lower prevalence. The key players are concentrating on the research and development of HD symptomatic treatments. An investigational medication called SRX246 is being created by Azevan Pharmaceuticals to treat the neuropsychiatric signs and symptoms of Huntington's disease. The medicine SRX246 functions by obstructing the brain's vasopressin 1a (V1a) receptor. The primary vasopressin receptor in the nervous system is the V1a receptor. By blocking the V1a receptor and preventing vasopressin from binding to the receptor, SRX246 causes the agitated and violent behaviour that is typical of people with Huntington's disease. The medications that are now approved, however, only treat the symptoms of the condition and offer palliative care. While drugs might lessen a patient's symptom intensity, they are frequently linked to side effects such as somnolence, gait problems, dysphagia, and apathy that can seriously impair a patient's quality of life. It is crucial to assess how these patients' Health-related Quality of Life (HRQOL) is affected given the lack of treatment for the illness. Early to mid-stage HD patients require integrated multidisciplinary healthcare treatments, such as counselling and assessments of cognitive function. As a result of various medicines' inability to show effectiveness or their high levels of toxicity, drug development for HD has encountered considerable challenges. Patients with early manifest and prodromal HD did not meet the pre-specified co-primary outcomes in Vaccinex Inc.'s phase II study of pepinemab. The Huntington's disease Cognitive Assessment Battery family comprising two cognitive tests and the Clinical Global Impression of Change (CGIC) did not reach statistical significance in the SIGNAL study's early manifestation sample. Due to the availability of medicine and patent protection, the symptomatic treatment category had the highest revenue share in the last year. The entrance of SAGE-718 and Cellavita-HD is expected to make disease-modifying treatments the market sector with the fastest growth over the next years. Instead of targeting the mutant protein, businesses are now concentrating on the development of drugs that can be injected into the brain to prevent the creation of mutant HTT protein. Early-stage pharmaceuticals with innovative targets include Cellavita HD (stem cell treatment) by Cellavita and Azidus Brazil, mHTT ZFP by Sangamo Therapeutics, Inc., and AMT-130 by UniQure (gene therapy). The market for the treatment of Huntington's disease is now dominated by the symptomatic treatment sector, which also had the highest revenue share. The availability of symptom management treatments and the patent protection afforded to these medications are to blame for this rise. When it comes to first-line treatment for chorea brought on by Huntington's disease, Xenazine and Austedo are recommended.

Impact of COVID-19 on the Global Huntington's Disease Market:

The worldwide COVID-19, however, caused a slowdown in the therapy market for Huntington's disease. Antidepressants, antipsychotics, and anticonvulsants were among the off-label medications sold by online pharmacies during the epidemic to treat HD symptoms. Clinical experiments during the COVID-19 pandemic were halted because to the government shutdown.

Scope of the report:

  • Market size available for the years: 2019-2032
  • Base year considered: 2021
  • Forecast Period: 2022-2032
  • Segments Covered: By Treatment
  • Regions Covered: Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
  • Companies Covered: Annexon Biosciences, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, H. Lundbeck A/S, Hetero, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc., SOM Biotech, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UniQure, Vaccinex, Inc.

Global Huntington's Disease Market Segmentation:

  • By Treatment: Based on the Treatment, Global Huntington's Disease Market is segmented as; Symptomatic treatment, Disease-modifying therapies.
  • By Region: Due to improved reimbursement infrastructure and the significant financial burden of HD in the United States and Canada, North America, which accounted for the greatest revenue share in previous year, is anticipated to dominate the market throughout the forecast period.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Huntington's Disease Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Huntington's Disease Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Huntington's Disease Market

7. Global Huntington's Disease Market, By Treatment, 2019-2032 (USD Million)

  • 7.1 Symptomatic treatment
  • 7.2 Disease-modifying therapies

8. Global Huntington's Disease Market, By Region, 2019-2032 (USD Million)

  • 8.1 Global Huntington's Disease Size and Market Share by Region (2019-2025)
  • 8.2 Global Huntington's Disease Size and Market Share by Region (2026-2032)
  • 8.3 Asia-Pacific
    • 8.3.1 Australia
    • 8.3.2 China
    • 8.3.3 India
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 Rest of Asia-Pacific
  • 8.4 Europe
    • 8.4.1 France
    • 8.4.2 Germany
    • 8.4.3 Italy
    • 8.4.4 Spain
    • 8.4.5 United Kingdom
    • 8.4.6 Rest of Europe
  • 8.5 Middle East and Africa
    • 8.5.1 Kingdom of Saudi Arabia
    • 8.5.2 United Arab Emirates
    • 8.5.3 Rest of Middle East & Africa
  • 8.6 North America
    • 8.6.1 Canada
    • 8.6.2 Mexico
    • 8.6.3 United States
  • 8.7 Latin America
    • 8.7.1 Argentina
    • 8.7.2 Brazil
    • 8.7.3 Rest of Latin America

9. Company Profiles

  • 9.1 Annexon Biosciences
    • 9.1.1 Company details
    • 9.1.2 Financial outlook
    • 9.1.3 Product summary
    • 9.1.4 Recent developments
  • 9.2 Bausch Health Companies Inc.
    • 9.2.1 Company details
    • 9.2.2 Financial outlook
    • 9.2.3 Product summary
    • 9.2.4 Recent developments
  • 9.3 Dr. Reddy's Laboratories Ltd
    • 9.3.1 Company details
    • 9.3.2 Financial outlook
    • 9.3.3 Product summary
    • 9.3.4 Recent developments
  • 9.4 Eli Lilly And Company
    • 9.4.1 Company details
    • 9.4.2 Financial outlook
    • 9.4.3 Product summary
    • 9.4.4 Recent developments
  • 9.5 H. Lundbeck A/S
    • 9.5.1 Company details
    • 9.5.2 Financial outlook
    • 9.5.3 Product summary
    • 9.5.4 Recent developments
  • 9.6 Hetero
    • 9.6.1 Company details
    • 9.6.2 Financial outlook
    • 9.6.3 Product summary
    • 9.6.4 Recent developments
  • 9.7 Hikma Pharmaceuticals PLC
    • 9.7.1 Company details
    • 9.7.2 Financial outlook
    • 9.7.3 Product summary
    • 9.7.4 Recent developments
  • 9.8 Lupin
    • 9.8.1 Company details
    • 9.8.2 Financial outlook
    • 9.8.3 Product summary
    • 9.8.4 Recent developments
  • 9.9 Medesis pharma SA
    • 9.9.1 Company details
    • 9.9.2 Financial outlook
    • 9.9.3 Product summary
    • 9.9.4 Recent developments
  • 9.10 Mitochon Pharmaceuticals
    • 9.10.1 Company details
    • 9.10.2 Financial outlook
    • 9.10.3 Product summary
    • 9.10.4 Recent developments
  • 9.11 Neurocrine bioscience Inc.
    • 9.11.1 Company details
    • 9.11.2 Financial outlook
    • 9.11.3 Product summary
    • 9.11.4 Recent developments
  • 9.12 Novartis
    • 9.12.1 Company details
    • 9.12.2 Financial outlook
    • 9.12.3 Product summary
    • 9.12.4 Recent developments
  • 9.13 PTC Therapeutics, Inc.
    • 9.13.1 Company details
    • 9.13.2 Financial outlook
    • 9.13.3 Product summary
    • 9.13.4 Recent developments
  • 9.14 SOM Biotech
    • 9.14.1 Company details
    • 9.14.2 Financial outlook
    • 9.14.3 Product summary
    • 9.14.4 Recent developments
  • 9.15 Sun Pharmaceutical Industries Ltd.
    • 9.15.1 Company details
    • 9.15.2 Financial outlook
    • 9.15.3 Product summary
    • 9.15.4 Recent developments
  • 9.16 Teva Pharmaceutical Industries Ltd.
    • 9.16.1 Company details
    • 9.16.2 Financial outlook
    • 9.16.3 Product summary
    • 9.16.4 Recent developments
  • 9.17 UniQure
    • 9.17.1 Company details
    • 9.17.2 Financial outlook
    • 9.17.3 Product summary
    • 9.17.4 Recent developments
  • 9.18 Vaccinex, Inc.
    • 9.18.1 Company details
    • 9.18.2 Financial outlook
    • 9.18.3 Product summary
    • 9.18.4 Recent developments

10. List of Abbreviations

11. Reference Links

12. Conclusion

13. Research Scope